# BioGenes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biogenes

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.biogenes.de
- Latest round: Series B (Jan 12, 2004)
- Investors on record: 2

## About

BioGenes GmbH is a Berlin-based biotechnology company specializing in custom antibody development and immunoassay services for the pharmaceutical and research sectors, delivering precision solutions for various applications.Founded in Berlin, Germany, BioGenes GmbH focuses on custom antibody solutions and immunoassays. Under the leadership of CEO Alexander Knoll, the company has maintained a consistent operational strategy without notable pivots. The firm has been involved in a financing deal on January 12, 2004, with IBB Beteiligungsgesellschaft and Essential Invest GmbH & Co. KGaA.BioGenes specializes in the development of custom antibody solutions and immunoassay services tailored for both industry and research applications. Their core offerings include bespoke monoclonal and polyclonal antibodies, custom immunoassays, and host cell protein (HCP) monitoring products. These services are integral to various phases of drug manufacturing, particularly in addressing HCP impurities that can affect drug efficacy and safety. BioGenes has established a diverse client base, including pharmaceutical companies and research institutions across more than 40 countries, indicating a robust global market presence. The company's expertise spans over 30 years, with a commitment to quality bolstered by ISO 9001:2015 certification, ensuring that all results and reagents remain the property of the customers.BioGenes operates on a B2B model, providing tailored services to pharmaceutical and biotechnology firms which require high-quality custom antibodies and immunoassays for their research and development efforts. The revenue structure is primarily based on project-based contracts, where clients engage BioGenes for specific services, such as the development of tailored HCP ELISA assays or antibody production. Each project is customized, allowing clients the flexibility to choose single services or complete packages, which may include consulting, assay development, and analytical testing. Detailed pricing structures are aligned with the complexity and scope of services offered, ensuring competitive and transparent pricing for their flagship products and services. Through direct collaboration with clients and ongoing support, BioGenes fosters long-term partnerships that contribute to sustained revenue growth.BioGenes GmbH plans to enhance its product offerings with new custom antibody solutions expected to launch in the coming years. The company aims to expand its market presence into new regions, specifically targeting the North American and Asia-Pacific markets by 2025. The funding raised in January 2004 will be utilized to support these initiatives, enhancing their capabilities in research and development.

## Funding rounds

- Series B, Jan 12, 2004 — IBB Ventures, Essential Invest GmbH & Co. KGaA

## Investors

- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Series B
- Essential Invest GmbH & Co. KGaA — Series B